Appili Ther Stock Price, News & Analysis

Appili Therapeutics (APLIF) announced that the independent Data and Safety Monitoring Board (DSMB) has endorsed the continuation of its Phase 3 PRESECO trial for Avigan/Reeqonus (favipiravir) without modifications. This trial is aimed at evaluating the drug as a potential treatment for mild-to-moderate COVID-19 patients. With approximately 600 subjects involved, Appili expects to report top-line results in Q3 2021. The drug has a well-established safety profile and is part of a consortium aimed at global development for COVID-19 treatment.

Appili Therapeutics (OTCQX:APLIF) announces that CEO Dr. Armand Balboni will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 10:00 AM ET. The conference is fully virtual, and Appili will conduct one-to-one meetings with attendees. A live webcast of the presentation will be available on the Company’s website, with a replay accessible afterward. Appili focuses on developing anti-infective drug candidates to combat urgent infections worldwide.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the Inaugural Emerging Growth Virtual Conference from March 17-19. CEO Dr. Armand Balboni will partake in a Fireside Chat on March 19 at 4:30 PM ET. The presentation is scheduled for March 19 at 2:30 PM ET, with opportunities for one-to-one meetings throughout the conference. Interested investors can register HERE. A replay will be available on Appili’s website after the event.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series focusing on infectious diseases, featuring notable experts like Dr. Scott Gottlieb and Dr. Syra Madad. The first event, scheduled for March 3 at 1:00 p.m. ET, will discuss pandemic response strategies and future infectious outbreaks. This initiative aims to enhance understanding and investment in treatments and public health policies. The company continues to support late-stage clinical trials for its antiviral candidate, highlighting its commitment to addressing urgent healthcare needs.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series on global infectious disease trends, starting on March 3, 2021, featuring prominent speakers including Dr. Scott Gottlieb and Dr. Syra Madad. The panel will focus on pandemic response strategies, treatment investments, and future infectious disease challenges. The event is free and open to the public with prior registration. Appili Therapeutics is actively involved in developing antiviral treatments, including late-stage trials for Avigan® / REEQONUS^TM for COVID-19.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the virtual Biocom Global conference from February 23-25, 2021. The presentation will focus on favipiravir, an antiviral therapy approved in Japan for influenza, and its potential use in treating COVID-19, alongside updates on their antifungal compound ATI-2307. The CEO, Armand Balboni, will host one-on-one investor meetings. The event features prominent speakers and highlights the importance of collaboration in addressing patient needs during the pandemic. For more details, visit biocomglobalpartnering.org.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) has announced a new webinar series focused on global infectious disease trends, starting with an event on March 3, featuring Dr. Scott Gottlieb. The series aims to explore challenges in combating COVID-19, including public health policies and new viral strains. The first session will include a Q&A segment and address the necessity for diverse treatments and public health strategies. Additionally, other events will be scheduled throughout the year, promoting ongoing discussions in the infectious disease sector.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) released its financial results for Q3 of FY2021, reporting a net loss of $9.34 million, up from $4.13 million in the same period the previous year. Key operational highlights include a collaboration with Dr. Reddy’s Laboratories to advance the COVID-19 antiviral favipiravir, and the initiation of clinical trials for its PRESECO study. As of December 31, 2020, the company had cash and short-term investments of $20.29 million. Appili remains committed to addressing COVID-19 through its antiviral programs.

Appili Therapeutics has appointed Rochelle Stenzler to its Board of Directors. Stenzler is a seasoned executive with a wealth of experience in healthcare, previously leading companies like TouchLogic Corporation and Revlon Canada. Her expertise in governance and leadership aims to support Appili during a critical phase in its development of favipiravir and other anti-infective programs. Stenzler's background includes significant roles in corporate governance, enhancing the board's capability to drive the company's mission against infectious diseases.